|
1
|
Poosiripinyo T, Sukpanichyingyong S,
Salang K, Sumananont C and Chobpenthai T: Recurrence leiomyosarcoma
of the popliteal vein: A rare soft tissue sarcoma. Case Rep Surg.
2023(2788584)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stork T, Hegedüs B, Guder W, Hamacher R,
Hardes J, Kaths M, Plönes T, Pöttgen C, Schildhaus HU, Streitbürger
A, et al: Prognostic factors for leiomyosarcoma with isolated
metastases to the lungs: Impact of metastasectomy. Ann Surg Oncol.
29:4429–4436. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Coindre JM, Terrier P, Guillou L, Le
Doussal V, Collin F, Ranchère D, Sastre X, Vilain MO, Bonichon F
and N'Guyen Bui B: Predictive value of grade for metastasis
development in adult soft tissue sarcomas: A Study of 1240 patients
from the French Federation of Cancer Centers Sarcoma Group. Cancer.
91:1914–1926. 2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Baio R, Intilla O, Molisso G, Di Mauro U,
Ferrante D, Di Lorenzo G, Buonerba C, Citarella R, Pagano T and
Sanseverino R: Primary leiomyosarcoma of the ureter: A case report.
Oncol Lett. 29(258)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Filho WMNE, Melo SMC, de Brito Alves R,
Junior LAS and da Fonseca Reis Silva D: Retromammary fat, axillary
and arm metastases from a retroperitoneal leiomyosarcoma: Report of
a case with an indolent behaviour. Ecancermedicalscience.
11(778)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kaur S, Tyagi R, Selhi P, Singh A, Puri H
and Sood N: Subcutaneous axillary and scalp metastases from
non-gynecological retroperitoneal leiomyosarcoma: An unusual
presentation after surgical resection. Rare Tumors.
7(5970)2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
De Giorgi V, Sestini S, Massi D, Papi F,
Alfaioli B and Lotti T: Superficial cutaneous leiomyosarcoma: A
rare, misleading tumor. Am J Clin Dermatol. 9:185–187.
2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Swallow CJ, Strauss DC, Bonvalot S,
Rutkowski P, Desai A, Gladdy RA, Gonzalez R, Gyorki DE, Fairweather
M, van Houdt WJ, et al: Management of primary retroperitoneal
sarcoma (RPS) in the Adult: An Updated consensus Approach from the
Transatlantic Australasian RPS Working Group. Ann Surg Oncol.
28:7873–7888. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sogaard AS, Laurberg JM, Sorensen M,
Sogaard OS, Wara P, Rasmussen P and Laurberg S: Intraabdominal and
retroperitoneal soft-tissue sarcomas-outcome of surgical treatment
in primary and recurrent tumors. World J Surg Oncol.
8(81)2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Brennan MF, Antonescu CR, Moraco N and
Singer S: Lessons learned from the Study of 10,000 patients with
soft tissue sarcoma. Ann Surg. 260:416–421; discussion 421-422.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Casali PG, Abecassis N, Aro HT, Bauer S,
Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG,
Brodowicz T, et al: Soft tissue and visceral sarcomas: ESMO-EURACAN
clinical Practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 29 (Suppl 4):iv51–iv67. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang WL, Bones-Valentin RA, Prieto VG,
Pollock RE, Lev DC and Lazar AJ: Sarcoma metastases to the skin: A
clinicopathologic study of 65 patients. Cancer. 118:2900–2904.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Øines MN, Smith HG, Preisler L and
Penninga L: Leiomyosarcoma of the abdomen and retroperitoneum: A
systematic review. Front Surg. 11(1375483)2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Clark MA, Fisher C, Judson I and Thomas
JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711.
2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Antonescu CR, Blay JY and Bovée MG: WHO
Classification of Tumours: Soft Tissue and Bone Tumours. IARC
Press, Lyon, 2020.
|
|
16
|
Weekes RG, McLeod RA, Reiman HM and
Pritchard DJ: CT of soft-tissue neoplasms. AJR Am J Roentgenol.
144:355–360. 1985.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Choi JH and Ro JY: Retroperitoneal
sarcomas: An Update on the Diagnostic pathology update Approach.
Diagnostics (Basel). 10(642)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Iwata J and Fletcher CD:
Immunohistochemical detection of cytokeratin and epithelial
membrane antigen in leiomyosarcoma: A systematic study of 100
cases. Pathol Int. 50:7–14. 2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mestiri S, Elghali MA, Bourigua R,
Abdessayed N, Nasri S, Amine BA, Missaoui N, Ben Maitig M, Hmissa
S, Sriha B and Mokni M: Soft tissue leiomyosarcoma-diagnostics
management and prognosis: Data of the registry cancer of the center
of Tunisia. Rare Tumors. 11(2036361318820171)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hashimoto H, Daimaru Y, Takeshita S,
Tsuneyoshi M and Enjoji M: Prognostic significance of histologic
parameters of soft tissue sarcomas. Cancer. 70:2816–2822.
1992.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Grimaudo MS, Renne SL, Colombo P, Giordano
L, Gennaro N, Laffi A, Cariboni U, Cananzi FCM, Ruspi L, Santoro A
and Bertuzzi AF: Prognostic value of mitotic count in
leiomyosarcoma: A comprehensive monocentric retrospective study.
Hum Pathol. 143:17–23. 2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rodríguez-Lomba E, Molina-López I,
Parra-Blanco V, Suárez-Fernández R and Pulido-Pérez A: Clinical and
histopathologic findings of cutaneous leiomyosarcoma: Correlation
with prognosis in 12 patients. Actas Dermosifiliogr (Engl Ed).
109:140–147. 2018.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
23
|
Zagars GK, Mullen JR and Pollack A:
Malignant fibrous histiocytoma: Outcome and prognostic factors
following conservation surgery and radiotherapy. Int J Radiat Oncol
Biol Phys. 34:983–994. 1996.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yoshimoto M, Yamada Y, Ishihara S, Kohashi
K, Toda Y, Ito Y, Yamamoto H, Furue M, Nakashima Y and Oda Y:
Comparative study of myxofibrosarcoma with undifferentiated
pleomorphic sarcoma: Histopathologic and clinicopathologic review.
Am J Surg Pathol. 44:87–97. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sugiura Y, Machinami R, Matsumoto S, Kanda
H, Ae K, Takazawa Y and Takeuchi K: Prognostic value of CD34
expression status in patients with in myxofibrosarcomas and
undifferentiated pleomorphic sarcomas. Sci Rep.
11(15494)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Scurr M: Histology-driven chemotherapy in
soft tissue sarcomas. Curr Treat Options Oncol. 12:32–45.
2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Judson I, Verweij J, Gelderblom H,
Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan
J, Hohenberger P, et al: Doxorubicin alone versus intensified
doxorubicin plus ifosfamide for first-line treatment of advanced or
metastatic soft-tissue sarcoma: A randomised controlled phase 3
trial. Lancet Oncol. 15:415–423. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
D'Ambrosio L, Touati N, Blay JY, Grignani
G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J,
Sanfilippo R, Katz D, et al: Doxorubicin plus dacarbazine
doxorubicin plus ifosfamide or doxorubicin alone as a first-line
treatment for advanced leiomyosarcoma: A propensity score matching
analysis from the European Organization for Research and Treatment
of Cancer Soft Tissue and Bone Sarcoma Group. Cancer.
126:2637–2647. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Garcia-del-Muro X, Lopez-Pousa A, Maurel
J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J,
Cruz J, Poveda A, et al: Randomized phase II study comparing
gemcitabine plus dacarbazine versus dacarbazine alone in patients
with previously treated soft tissue sarcoma: A Spanish Group for
Research on Sarcomas study. J Clin Oncol. 29:2528–2533.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Seddon B, Strauss SJ, Whelan J, Leahy M,
Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, et al:
Gemcitabine and docetaxel versus doxorubicin as first-line
treatment in previously untreated advanced unresectable or
metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled
phase 3 trial. Lancet Oncol. 18:1397–1410. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Pautier P, Italiano A, Piperno-Neumann S,
Chevreau CM, Penel N, Firmin N, Boudou Rouquette P, Bertucci F, Le
Brun-Ly V, Ray-Coquard IL, et al: A randomised, multicenter
phase-III study comparing doxorubicin (dox) alone versus dox with
trabectedin (trab) followed by trab in non-progressive patients
(pts) as first-line therapy, in pts with metastatic or unresectable
leiomyosarcoma (LMS): Final results of the LMS-04 study (Abstract
1913O). Ann Oncol. 34(S1030)2023.
|
|
32
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chi Y, Yao Y and Wang SS: Anlotinib for
metastatic STS: Randomized trial. J Clin Oncol. 36 (Suppl 15)(abstr
11503)2018.
|
|
34
|
Zhuang RY, Liu WS and Wang ZM: Anlotinib +
chemotherapy in advanced LMS. Zhonghua Zhuanyi Zhongliu Zazhi.
4:106–111. 2021.(In Chinese).
|
|
35
|
Tap WD, Wagner AJ, Schoffski P,
Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR,
Spira A, Kawai A, et al: Effect of Doxorubicin plus olaratumab vs
doxorubicin plus placebo on survival in patients with advanced soft
tissue sarcomas: The ANNOUNCE Randomized Clinical trial. JAMA.
323:1266–1276. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Burgess MA, Bolejack V and Schuetze S:
Pembrolizumab in UPS and pleomorphic LPS: SARC028 final results. J
Clin Oncol. 37 (Suppl 15)(S11015)2019.
|
|
37
|
Saerens M, Brusselaers N, Rotteys
Decruyenaere A, Creytens D and Lapeire L: Immune checkpoint
inhibitors in treatment of soft-tissue sarcoma: A systematic review
and meta-analysis. Eur J Cancer. 152:165–182. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
D'Angelo SP, Mahoney MR, Van Tine BA,
Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap
WD, Schwartz GK and Streicher H: Nivolumab with or without
ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two
open-label, non-comparative, randomised, phase 2 trial. Lancet
Oncol. 19:416–426. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wilky BA, Maleddu A, Mailhot A, Cartwright
C, Gao D, Moreno Tellez C, Powers K, Kemp L, Therrien N, Patel JM,
et al: A single-arm, open-label phase 2 trial of doxorubicin plus
zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1
inhibitor, in patients with advanced/metastatic soft tissue
sarcomas (Abstract 11501). J Clin Oncol. 41(11501)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Reichardt P, Andreou D, Flörcken A, Groß
T, Richter S, Kessler T, Kortüm M, Schmidt CA, Kasper B, Wardelmann
E, et al: Efficacy and safety of nivolumab and trabectedin in
pretreated patients with advanced soft tissue sarcomas (STS):
Results of a phase II trial of the German Interdisciplinary Sarcoma
Group (GISG-15, NitraSarc) (Abstract 11500). J Clin Oncol.
41(11500)2023.
|
|
41
|
Martin-Broto J, Diaz Beveridge R, Moura D,
Ramos R, Martinez-Trufero J, Carrasco-Garcia I, Lopez-Pousa A,
Gonzalez-Billalabeitia E, Gutierrez A, Cruz Jurado J, et al:
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of
doxorubicin and dacarbazine plus nivolumab in first-line treatment
of advanced leiomyosarcoma (Abstract 11502). J Clin Oncol.
41(11502)2023.
|
|
42
|
Jensen ML, Jensen OM, Michalski W, Nielsen
OS and Keller J: Intradermal and subcutaneous leiomyosarcoma: A
clinicopathological and immunohistochemical study of 41 cases. J
Cutan Pathol. 23:458–463. 1996.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gronchi A, Miah AB, Dei Tos AP, Abecassis
N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, et
al: Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS
clinical practice guidelines for diagnosis, treatment and
follow-up☆. Ann Oncol. 32:1348–1365. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Guillou L, Coindre JM, Bonichon F, Nguyen
BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V,
Leroux A, et al: Comparative study of the National Cancer Institute
and French Federation of Cancer Centers Sarcoma Group grading
systems in a population of 410 adult patients with soft tissue
sarcoma. J Clin Oncol. 15:350–362. 1997.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gootee J, Sioda N, Aurit S, Curtin C and
Silberstein P: Important Prognostic factors in leiomyosarcoma
survival: A National Cancer Database (NCDB) analysis. Clin Transl
Oncol. 22:860–869. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gladdy RA, Qin LX, Moraco N, Agaram NP,
Brennan MF and Singer S: Predictors of Survival and recurrence in
primary leiomyosarcoma. Ann Surg Oncol. 20:1851–1857.
2013.PubMed/NCBI View Article : Google Scholar
|
